El futuro es ahora: terapias prometedoras

Álvaro J. Ruiz; Rafael Campo; Alejandro Román-González; Raúl D. Santos

doi:10.24875/RCCAR.M23000215

El futuro es ahora: terapias prometedoras

Translated title of the contribution: The future is now: promising therapies

Álvaro J. Ruiz, Rafael Campo, Alejandro Román-González, Raúl D. Santos

Research output: Contribution to journal › Article › peer-review

Abstract

Statins do not always allow the recommended goals to be met. Recent and future options for dyslipidemias are reviewed. Triglycerides: Pemafibrate affects triglycerides and LDL-c but has not yet shown changes in hard outcomes. Ethyl icosapentate reduced events, probably due to an anti-inflammatory effect. LDL cholesterol: Inclisiran, a synthetic small interfering RNA (siRNA), reduces LDL-c up to 83%. Confirmation of MACE reduction is lacking. PCSK9: MK-0616 is in Phase IIb. Gemcabene inhibits cholesterol and fatty acid synthesis and has anti-inflammatory properties. ANGPTL3: Evinacumab reduces triglycerides and HDL-c and is already approved for homozygous familial hypercholesterolemia. ARO_ANG3 is in Phase II. Gene therapy: Two strategies have been successfully used: gene transfer and gene editing. Lp(a): Pelacarsen, in Phase II, interferes with Lp(a) production. Olpasiran prevents Lp(a) assembly, with reductions of up to 95%. SLN360 can prevent Lp(a) production by up to 98%.

Translated title of the contribution	The future is now: promising therapies
Original language	Spanish
Pages (from-to)	45-53
Number of pages	9
Journal	Revista Colombiana de Cardiologia
Volume	30
DOIs	https://doi.org/10.24875/RCCAR.M23000215
State	Published - 2023

Access to Document

10.24875/RCCAR.M23000215

Cite this

@article{690e7f16551e4b5d801a773e146c3ebd,

title = "El futuro es ahora: terapias prometedoras",

abstract = "Statins do not always allow the recommended goals to be met. Recent and future options for dyslipidemias are reviewed. Triglycerides: Pemafibrate affects triglycerides and LDL-c but has not yet shown changes in hard outcomes. Ethyl icosapentate reduced events, probably due to an anti-inflammatory effect. LDL cholesterol: Inclisiran, a synthetic small interfering RNA (siRNA), reduces LDL-c up to 83%. Confirmation of MACE reduction is lacking. PCSK9: MK-0616 is in Phase IIb. Gemcabene inhibits cholesterol and fatty acid synthesis and has anti-inflammatory properties. ANGPTL3: Evinacumab reduces triglycerides and HDL-c and is already approved for homozygous familial hypercholesterolemia. ARO_ANG3 is in Phase II. Gene therapy: Two strategies have been successfully used: gene transfer and gene editing. Lp(a): Pelacarsen, in Phase II, interferes with Lp(a) production. Olpasiran prevents Lp(a) assembly, with reductions of up to 95%. SLN360 can prevent Lp(a) production by up to 98%.",

keywords = "ANGPTL3, PCSK9, gene therapy, siRNA",

author = "Ruiz, {{\'A}lvaro J.} and Rafael Campo and Alejandro Rom{\'a}n-Gonz{\'a}lez and Santos, {Ra{\'u}l D.}",

note = "Publisher Copyright: {\textcopyright} 2022 Sociedad Colombiana de Cardiolog{\'i}a y Cirug{\'i}a Cardiovascular. Publicado por Permanyer.",

year = "2023",

doi = "10.24875/RCCAR.M23000215",

language = "Espa{\~n}ol ",

volume = "30",

pages = "45--53",

journal = "Revista Colombiana de Cardiologia",

issn = "0120-5633",

publisher = "Permanyer Publications Ltd",

}

TY - JOUR

T1 - El futuro es ahora

T2 - terapias prometedoras

AU - Ruiz, Álvaro J.

AU - Campo, Rafael

AU - Román-González, Alejandro

AU - Santos, Raúl D.

PY - 2023

Y1 - 2023

N2 - Statins do not always allow the recommended goals to be met. Recent and future options for dyslipidemias are reviewed. Triglycerides: Pemafibrate affects triglycerides and LDL-c but has not yet shown changes in hard outcomes. Ethyl icosapentate reduced events, probably due to an anti-inflammatory effect. LDL cholesterol: Inclisiran, a synthetic small interfering RNA (siRNA), reduces LDL-c up to 83%. Confirmation of MACE reduction is lacking. PCSK9: MK-0616 is in Phase IIb. Gemcabene inhibits cholesterol and fatty acid synthesis and has anti-inflammatory properties. ANGPTL3: Evinacumab reduces triglycerides and HDL-c and is already approved for homozygous familial hypercholesterolemia. ARO_ANG3 is in Phase II. Gene therapy: Two strategies have been successfully used: gene transfer and gene editing. Lp(a): Pelacarsen, in Phase II, interferes with Lp(a) production. Olpasiran prevents Lp(a) assembly, with reductions of up to 95%. SLN360 can prevent Lp(a) production by up to 98%.

AB - Statins do not always allow the recommended goals to be met. Recent and future options for dyslipidemias are reviewed. Triglycerides: Pemafibrate affects triglycerides and LDL-c but has not yet shown changes in hard outcomes. Ethyl icosapentate reduced events, probably due to an anti-inflammatory effect. LDL cholesterol: Inclisiran, a synthetic small interfering RNA (siRNA), reduces LDL-c up to 83%. Confirmation of MACE reduction is lacking. PCSK9: MK-0616 is in Phase IIb. Gemcabene inhibits cholesterol and fatty acid synthesis and has anti-inflammatory properties. ANGPTL3: Evinacumab reduces triglycerides and HDL-c and is already approved for homozygous familial hypercholesterolemia. ARO_ANG3 is in Phase II. Gene therapy: Two strategies have been successfully used: gene transfer and gene editing. Lp(a): Pelacarsen, in Phase II, interferes with Lp(a) production. Olpasiran prevents Lp(a) assembly, with reductions of up to 95%. SLN360 can prevent Lp(a) production by up to 98%.

KW - ANGPTL3

KW - PCSK9

KW - gene therapy

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=85176252563&partnerID=8YFLogxK

U2 - 10.24875/RCCAR.M23000215

DO - 10.24875/RCCAR.M23000215

M3 - Artículo

AN - SCOPUS:85176252563

SN - 0120-5633

VL - 30

SP - 45

EP - 53

JO - Revista Colombiana de Cardiologia

JF - Revista Colombiana de Cardiologia

ER -

El futuro es ahora: terapias prometedoras

Abstract

Access to Document

Other files and links

Fingerprint

Cite this